Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02931565 · ClinicalTrials.gov registry record · Phase 2
Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type I or II Achalasia
A Phase 2 study, sponsored by Cyclerion Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT02931565 is a Phase 2 study that was terminated before completion, run by Cyclerion Therapeutics. The registered enrollment target is 9 participants.
The verdict
NCT02931565, a Phase 2 study, was terminated before completion, sponsored by Cyclerion Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The objectives of this study are as follows: In participants with primary Type I or II achalasia, following a single 5-mg dose of olinciguat (IW-1701), * To assess the safety and tolerability * To determine the effects on measures of esophageal function by high-resolution impedance manometry (HRIM) * To determine the pharmacokinetic (PK) parameters
Interventions
- DRUG Matching Placebo
- DRUG Olinciguat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2017-04-06 |
| Est. Completion | 2018-05-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02931565
The ClinicalTrials.gov registry entry for NCT02931565 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cyclerion Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matching Placebo is the first listed.
NCT02931565 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02931565 about?
NCT02931565 is a clinical study titled "Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type I or II Achalasia". The objectives of this study are as follows: In participants with primary Type I or II achalasia, following a single 5-mg dose of olinciguat (IW-1701), * To assess the safety and tolerability * To determine the effects on measures of esophageal function by high-resolution impedance manometry (HRIM...
What is the current status of trial NCT02931565?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2017-04-06. Estimated completion is 2018-05-01.
What interventions are being tested in trial NCT02931565?
The interventions under investigation include: Matching Placebo (DRUG), Olinciguat (DRUG).
Who is sponsoring clinical trial NCT02931565?
This trial is sponsored by Cyclerion Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.